Applied Genetic Technologies (AGTC) Posts Q4 Loss of 48c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Reaffirms Applied Genetic (AGTC) at 'Buy' Following FY15 Results; Fundamental Thesis Remains Unchanged
September 11, 2015 8:29 AM EDTRoth Capital reaffirms its Buy rating and $34 price target on Applied Genetic Technologies (Nasdaq: AGTC) following Q4, FY15 results reported Thursday night.
Analyst Joseph Pantginis noted that AGTC reported FY15 loss of $1.50 per share, versus the firm's loss expectation of $1.37 per share.
Pantginis commented, We believe... More
